These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 34657238)
1. A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis. Kawakatsu S; Zhu R; Zhang W; Tang MT; Lu T; Quartino AL; Kågedal M J Pharmacokinet Pharmacodyn; 2022 Apr; 49(2):179-190. PubMed ID: 34657238 [TBL] [Abstract][Full Text] [Related]
2. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ; Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039 [TBL] [Abstract][Full Text] [Related]
3. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG; Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037 [TBL] [Abstract][Full Text] [Related]
5. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S; Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038 [TBL] [Abstract][Full Text] [Related]
6. Predictors of Placebo Induction Response and Remission in Ulcerative Colitis. Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1050-1060.e9. PubMed ID: 36029969 [TBL] [Abstract][Full Text] [Related]
7. Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial. Nagahori M; Watanabe K; Motoya S; Ogata H; Kanai T; Matsui T; Suzuki Y; Pinton P; Ursos L; Sakamoto S; Shikamura M; Hori T; Fernandez J; Hibi T; Watanabe M Digestion; 2021; 102(5):742-752. PubMed ID: 33454706 [TBL] [Abstract][Full Text] [Related]
8. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Jairath V; Zou GY; Parker CE; MacDonald JK; AlAmeel T; Al Beshir M; Almadi MA; Al-Taweel T; Atkinson NS; Biswas S; Chapman T; Dulai PS; Glaire MA; Hoekman DR; Koutsoumpas A; Minas E; Mosli MH; Samaan M; Khanna R; Travis S; D'Haens G; Sandborn WJ; Feagan BG Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011572. PubMed ID: 28886205 [TBL] [Abstract][Full Text] [Related]
9. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625 [TBL] [Abstract][Full Text] [Related]
10. A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. Jairath V; Jeyarajah J; Zou G; Parker CE; Olson A; Khanna R; D'Haens GR; Sandborn WJ; Feagan BG Lancet Gastroenterol Hepatol; 2019 Jan; 4(1):63-70. PubMed ID: 30343116 [TBL] [Abstract][Full Text] [Related]
11. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921 [TBL] [Abstract][Full Text] [Related]
13. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Jairath V; Khanna R; Zou GY; Stitt L; Mosli M; Vandervoort MK; D'Haens G; Sandborn WJ; Feagan BG; Levesque BG Aliment Pharmacol Ther; 2015 Nov; 42(10):1200-10. PubMed ID: 26388424 [TBL] [Abstract][Full Text] [Related]